Aveo Licenses Tricky Tivozanib To EUSA In Europe
This article was originally published in Scrip
Executive Summary
If Aveo Oncology's lead cancer drug candidate tivozanib was a cat, it would be on its eighth out of nine lives by now, the latest of which involves an ex-US partnership with EUSA Pharma that offers a small $2.5m upfront payment, but potentially lucrative milestone fees totaling as much as $394m.
You may also be interested in...
Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq
The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.
Finance Watch: VC Mega-Rounds Are Alive And Well
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.